Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Allergy & Immunology
•
Eosinophilic Disorders
What treatment options do you consider if eosinophilia with end organ dysfunction persists with q8 week dosing of benralizumab and you can't obtain approval for q4 week dosing?
Related Questions
How often do you monitor the eosinophil count after initiating anti-IL5 therapy for HAE?
What is your approach to biologic selection in a patient with resistant/persistent ABPA?
Would you ever use dupilumab for atopic dermatitis in a patient who also has EGPA?
How often do you monitor the eosinophil count after initiating anti-IL5 therapy for HES?
How long would you treat severe eosinophilic asthma/pneumonia with q4week anti-IL5 therapy prior to tapering?
What parasites do you screen for in your workup of HES?
Would you favor treating HES manifesting with EoE with dupilumab or anti-IL5 therapy?
What treatment approach do you suggests for a patient with nasal polyp disease and asthma who was improved on dupilumab, but over last 2 years has begun to have increased nasal symptoms and rising eosinophil counts?
How would you approach an asymptomatic older female patient with eosinophilia to 17,000, present for years, and normal eosinophilia workup including marrow and negative FLIP1?
Is there any non-invasive validated testing for Annatto (E-160b), also known as norbixin?
